---
title: "SERB Pharmaceuticals buys RSDL!"
description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member."
url: "https://cbrneworld.com/news/subscribers/serb-pharmaceuticals-buys-rsdl"
date: "2026-07-30T21:06:58+00:00"
language: "en-GB"
---

#  SERB Pharmaceuticals buys RSDL!

 Written by Zoe Rutherford on 01 August 2024.

[SERB Pharmaceuticals](https://serb.com/), a global specialty pharmaceutical company, announced today the acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE: EBS) for an up-front payment of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon first achievement of a milestone relating to sourcing of certain components of RSDL®. As part of the transaction, SERB will also acquire and maintain the operation of the leased manufacturing facility in Hattiesburg, Mississippi and several employees who support the site and RSDL® product will join SERB.

RSDL® is a medical device provided as a kit, with a lotion impregnated sponge in a packet, intended to remove or neutralize chemical warfare agents from the skin. RSDL removes or neutralizes chemical warfare agents (CWAs) including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas, and T-2 toxin. RSDL® is the only FDA-cleared device backed by 20 years of clinical data, that can remove or neutralize chemical warfare agents from the skin in one step. Over 15 million packets of RSDL® have been sold in over 30 countries.

“The acquisition of RSDL® strengthens our position as the leading provider of medical countermeasures for chemical, biological, radiological and nuclear threats," said Jeremie Urbain, Chairman of SERB Pharmaceuticals. “Alongside our broad portfolio of antidotes and preventive medicines, RSDL® will give SERB new opportunities to support and partner with governments, militaries, NGOs and emergency preparedness agencies around the world.”

RSDL® was initially developed by Defence Research and Development Canada, an agency of the Canadian Department of National Defence, to prepare the Canadian forces for chemical warfare attacks. RSDL® was 510(k) cleared by the FDA in 2003 and was subsequently issued a European CE Mark, and approval by Health Canada, the Australian Therapeutic Goods Administration and Israeli Ministry of Health.

 [CBRNe](https://cbrneworld.com/component/tags/tag/cbrne), [Acquisition](https://cbrneworld.com/component/tags/tag/acquisition)

## Schema

```json
{ "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "News", "item": "https://cbrneworld.com/news" }, { "@type": "ListItem", "position": 2, "name": "Subscribers", "item": "https://cbrneworld.com/news/subscribers" }, { "@type": "ListItem", "position": 3, "name": "SERB Pharmaceuticals buys RSDL!", "item": "https://cbrneworld.com/news/subscribers/serb-pharmaceuticals-buys-rsdl" } ] }
```

```json
{ "@context": "https://schema.org", "@type": "NewsArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://cbrneworld.com/news/subscribers/serb-pharmaceuticals-buys-rsdl" }, "headline": "SERB Pharmaceuticals buys RSDL!", "description": "SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today the acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. (NYSE: EBS) for an up-front payment of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon first achievement of a milestone relating to sourcing of certain components of RSDL®. As part of the transaction, SERB will also acquire and maintain the operation of the leased manufacturing facility in Hattiesburg, Mississippi and several employees who support the site and RSDL® product will join SERB.  RSDL® is a medical device provided as a kit, with a lotion impregnated sponge in a packet, intended to remove or neutralize chemical warfare agents from the skin. RSDL removes or neutralizes chemical warfare agents (CWAs) including: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas, and T-2 toxin.  RSDL® is the only FDA-cleared device backed by 20 years of clinical data, that can remove or neutralize chemical warfare agents from the skin in one step.  Over 15 million packets of RSDL® have been sold in over 30 countries. “The acquisition of RSDL® strengthens our position as the leading provider of medical countermeasures for chemical, biological, radiological and nuclear threats," said Jeremie Urbain, Chairman of SERB Pharmaceuticals. “Alongside our broad portfolio of antidotes and preventive medicines, RSDL® will give SERB new opportunities to support and partner with governments, militaries, NGOs and emergency preparedness agencies around the world.” RSDL® was initially developed by Defence Research and Development Canada, an agency of the Canadian Department of National Defence, to prepare the Canadian forces for chemical warfare attacks. RSDL® was 510(k) cleared by the FDA in 2003 and was subsequently issued a European CE Mark, and approval by Health Canada, the Australian Therapeutic Goods Administration and Israeli Ministry of Health.", "image": { "@type": "ImageObject", "url": "https://cbrneworld.com/" }, "publisher": { "@type": "Organization", "name": "CBRNe World Magazine", "logo": { "@type": "ImageObject", "url": "https://cbrneworld.com/images/default/Asset%201.png" } }, "author": { "@type": "Person", "name": "Zoe Rutherford", "url": "https://cbrneworld.com/news/subscribers/serb-pharmaceuticals-buys-rsdl" }, "datePublished": "2024-08-01T16:13:16+01:00", "dateCreated": "2024-08-01T16:13:16+01:00", "dateModified": "2024-08-01T16:13:16+01:00" }
```